TCGA-KQ-A41P-01A-12R-A33J-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 35.93955322
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.410
- MYOGENESIS+0.340
- COAGULATION+0.310
- OXIDATIVE_PHOSPHORYLATION+0.300
- ANGIOGENESIS+0.270
- PANCREAS_BETA_CELLS+0.260
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
- APICAL_SURFACE+0.240
- ESTROGEN_RESPONSE_LATE+0.220
- KRAS_SIGNALING_UP+0.210
Top 10 suppressed
- MYC_TARGETS_V1-0.520
- G2M_CHECKPOINT-0.490
- E2F_TARGETS-0.480
- MITOTIC_SPINDLE-0.480
- PROTEIN_SECRETION-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.440
- MTORC1_SIGNALING-0.410
- INTERFERON_ALPHA_RESPONSE-0.390
- DNA_REPAIR-0.380
- PI3K_AKT_MTOR_SIGNALING-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OL-A66N-01A-12R-A31O-07 | — | B | 0.885 |
| 2 | SRR1487321 | GTEX | — | 0.882 |
| 3 | SRR1488651 | GTEX | — | 0.881 |
| 4 | 60c210ff-d245-40d2-9de9-7b799cc3ffc9 | — | — | 0.873 |
| 5 | SRR1433431 | GTEX | — | 0.869 |
| 6 | d93b1580-c20d-4611-ac99-c0cb33f37a45 | — | — | 0.867 |
| 7 | SRR1441546 | GTEX | — | 0.856 |
| 8 | MNG513 | — | — | 0.853 |
| 9 | SRR1405007 | GTEX | — | 0.852 |
| 10 | TCGA-XF-A8HF-01A-11R-A36F-07 | — | — | 0.852 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.410 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.270 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.210 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.090 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.090 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.080 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.070 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.020 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |
| COMPLEMENT | 0.010 | Inavolisib | — uncovered |